Bringing New Hope to Treatment-Resistant Depression

Cyclerion is a biopharmaceutical company dedicated to advancing the first personalized therapeutic approach for people living with treatment-resistant depression (TRD), a condition with significant unmet medical need. Our novel approach combines proven therapies with cutting-edge technologies, offering the potential to deliver a more effective, safer, and less burdensome solution for those with severe and persistent depression.

Creating the first individualized TRD treatment

The future of mental health treatment lies in personalized medicine—tailoring therapies to each patient’s unique biology and needs. Our lead program is focused on resetting dysregulated brainwave patterns in people with TRD by pairing generic anesthetics with a personalized biofeedback-driven device.

Grounded in clinical evidence, this method is designed to maximize safety and efficacy, offering an alternative to electroconvulsive therapy (ECT), the current standard of care for TRD. Our vision is to transform care and offer real hope for people with this disease who have not responded to traditional treatments.

Learn more about our pioneering therapeutic approach to TRD

Meet the team

Our committed team of industry leaders, researchers and clinicians leverages its expertise and connections to external specialists in the field of neuropsychiatric therapy. This knowledge is the drive behind clinical validation and regulatory approval, with the goal of bringing this neuropsychiatric therapeutic approach to market in the coming years.

Leadership

Regina Graul, PhD

Board of Directors

Errol De Souza, PhD, Chair Regina Graul, PhD Peter Hecht, PhD Michael Higgins Steven Hyman, MD Dina Katabi, PhD 

Transforming innovation into impact

By prioritizing patient needs and treatment outcomes, our strategy is also designed to maximize stakeholder investment. We are well positioned to accelerate the development of groundbreaking therapies while delivering strong returns through evidence-driven investment.

Connect with us to learn more about partnering in the future of mental health care

Top